André Pfob retweetledi

Axillary surgery → CDK4/6 eligibility: what’s the real gain?
🔍5 RCTs, n=19,541
➡️Patients needed to prevent 1 event:
→ iDFS: 106–123
→ DDFS: 119–129
→ OS: 345–807
CDK4/6 benefit exists, but:
→ Grade ≥3 AEs: ~50–60%
→ ↑ Lymphedema: +3.9% (SLNB), +10.6% (cALND)
💬Using axillary surgery solely to guide CDK4/6 therapy → high NNT, added morbidity, marginal OS gain
thelancet.com/journals/lanon…



English























